Evidence map›Paper›PMID 30603293›Full record

ArticleDiabetology international2016

A comparison of IDeg + IAsp versus IDet + IAsp in subjects with type 1 diabetes: subgroup analysis of Japanese subjects.

Y Ono, T Nishida, J Hyllested-Winge, H Seino, T Sasaki

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Y OnoYuri Ono Clinic, Diabetes, Internal Medicine, Sapporo Fukoku-Seimei-Ekimaedori Building 31-7, Kita-2, Nishi-3, Chuo-Ku, Sapporo, 060-0002 Japan.
T NishidaNovo Nordisk Pharma Ltd, Tokyo, Japan.
J Hyllested-WingeNovo Nordisk Pharma Ltd, Tokyo, Japan.
H SeinoSeino Internal Medicine Clinic, Fukushima, Japan.
T SasakiSasaki Hospital Internal Medicine, Hokkaido, Japan.
Ono Clinic · JPSasaki Institute · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveEfficacy and safety were compared between insulin degludec (IDeg) once daily (OD) in combination with mealtime insulin aspart (IAsp) and insulin detemir (IDet) OD or twice daily (BID) in combination with mealtime IAsp in Japanese subjects with type 1 diabetes mellitus (T1DM). MATERIALS AND

methodsThis was a post hoc analysis of a multinational, controlled, open-label, parallel-group, treat-to-target trial that randomised adults [aged ≥18 years (≥20 years for Japan)] with T1DM for ≥12 months to basal IDeg OD (

resultsThe estimated mean change in HbA

conclusionThe findings were consistent with those of the global trial population. IDeg + IAsp may represent an improvement on current standard treatments for Japanese patients with T1DM.

Indexed as

Bolus treatmentInsulinJapaneseType 1 diabetes mellitus

Identifiers

PMID30603293
PMCPMC6224976
OpenAlexW2330756642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.